Literature DB >> 2454227

A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAc alpha(2----6)GalNAc, in mucin-type glycoproteins.

A Kurosaka1, H Kitagawa, S Fukui, Y Numata, H Nakada, I Funakoshi, T Kawasaki, T Ogawa, H Iijima, I Yamashina.   

Abstract

The structure of an epitopic carbohydrate recognized by a monoclonal antibody, MLS 102, was determined. A disaccharide, NeuAc alpha (2----6)GalNAc, the major prosthetic group of ovine submaxillary mucin (OSM) and related synthetic glycosides, NeuAc alpha(2----6)GalNAc alpha----Ser, NeuAc alpha(2----6)GalNAc beta----Ser, and NeuAc alpha (2----6)GalNAc beta----propyl, reacted with MLS 102 to similar extents, but the reaction was considerably weaker compared to that of OSM. This difference in reactivity could be ascribed to the occurrence of a cluster of the disaccharide on OSM. Purification of MLS 102-reactive antigens from a Triton X-100 extract of LS 180 cells by means of immunoaffinity chromatography gave mucin fractions (cMLS 102 antigen) with an OSM-like domain. Correlation between the content of the disaccharide, NeuAc alpha(2----6)GalNAc, in mucins and their reactivity with MLS 102 was observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454227

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  The glycosynapse.

Authors:  Sen-itiroh Hakomori Si
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

2.  Characterization of a carbohydrate epitope defined by the monoclonal antibody H185: sialic acid O-acetylation on epithelial cell-surface mucins.

Authors:  Pablo Argüeso; Mika Sumiyoshi
Journal:  Glycobiology       Date:  2006-08-29       Impact factor: 4.313

3.  Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism.

Authors:  Vittorio Fineschi; Irene Riezzo; Santina Cantatore; Cristoforo Pomara; Emanuela Turillazzi; Margherita Neri
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

4.  Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.

Authors:  M A Reddish; L Jackson; R R Koganty; D Qiu; W Hong; B M Longenecker
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

5.  Aggregation of oral bacteria by human salivary mucins in comparison to salivary and gastric mucins of animal origin.

Authors:  H M Koop; M Valentijn-Benz; A V Nieuw Amerongen; P A Roukema; J de Graaff
Journal:  Antonie Van Leeuwenhoek       Date:  1990-11       Impact factor: 2.271

6.  Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract.

Authors:  G Ohshio; T Imamura; M Imamura; H Yamabe; H Sakahara; H Nakada; I Yamashina
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Monoclonal antibody BA-1 to the human B lymphocyte marker CD24 recognizes a sialic acid (N-acetylneuraminic acid) dependent epitope in multi-valent display on peptide.

Authors:  H Mehmet; M Larkin; P W Tang; T W Lebien; T Feizi
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

8.  Immunoscintigraphy of colorectal cancer using 111In-labeled monoclonal antibody to mucin.

Authors:  H Sakahara; H Onodera; M Shirato; Z Yao; G Ohshio; H Kobayashi; M Hosono; S Yano; H Nakada; M Imamura
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

9.  Specificity of human anti-carbohydrate IgG antibodies as probed with polyacrylamide-based glycoconjugates.

Authors:  E P Smorodin; O A Kurtenkov; B L Sergeyev; G V Pazynina; N V Bovin
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

10.  Reduced bone marrow uptake of indium-111 labelled monoclonal antibody after radiotherapy.

Authors:  H Sakahara; H Onodera; H Kobayashi; Z Yao; I Yamashina; J Konishi
Journal:  Eur J Nucl Med       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.